Related Experiment Videos
Neurokinin receptor antagonists.
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Neurokinin receptor (NKr) antagonists show promise for treating emesis and depression. Further clinical trials are underway to explore their potential in other conditions, marking an exciting phase for human proof-of-concept studies.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Discovery
Background:
- Recent advancements in developing selective, orally-active neurokinin receptor (NKr) antagonists.
- Growing evidence for the involvement of tachykinin peptides in various biological functions.
Purpose of the Study:
- To review the progress and potential applications of NKr antagonists.
- To highlight the transition of NKr antagonists from animal models to human clinical trials.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of the efficacy and limitations of NKr antagonists in preclinical and clinical studies.
Main Results:
- NKr antagonists have shown efficacy in treating emesis and depression.
- Some NKr antagonists have progressed to clinical trials, with initial results published.
- Disappointing results were observed in some therapeutic areas, but human proof-of-concept is emerging.
Conclusions:
- The field of NKr antagonists is entering a crucial phase of human proof-of-concept.
- Continued research may expand the therapeutic indications for NKr antagonists.
- Numerous drug candidates are in clinical trials, suggesting a broadening potential for NKr antagonist applications.